FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2187888308> ?p ?o ?g. }

• W2187888308 endingPage "924" @default.
• W2187888308 startingPage "917" @default.
• W2187888308 abstract "To assess the impact on immunological, virological and metabolic parameters of replacing protease inhibitors (PIs) with efavirenz and replacing stavudine with tenofovir in HIV-infected children.A 48-week prospective evaluation of 28 HIV-infected children, with stable undetectable HIV-1 loads, who were taking highly active antiretroviral therapy (HAART) containing lamivudine, stavudine and a PI. Individuals were randomized to switch PI to efavirenz and stavudine to tenofovir at baseline (Group 1) or at week 24 (Group 2). Patient assessment included: clinical evaluation, viral load, CD4+ T-cell count, fasting blood levels and urine samples.All individuals maintained HIV RNA <50 copies/ml and unchanged CD4+ T-cell count through week 48. In Group 1 individuals, a significant decrease in cholesterol (P < 0.05), cholesterol:high-density lipoprotein (HDL) ratio (P < 0.01) and triglycerides (P < 0.05) was observed 24 and 48 weeks after the switch of HAART. The percentage of Group 1 children with increased cholesterol and triglycerides markedly decreased over the study period (from 43% to 0% and from 36% to 7%, respectively). In Group 2 individuals, unchanged lipids in the 24 weeks prior to the switch of HAART and a significant improvement on cholesterol (P < 0.05), cholesterol:HDL ratio (P < 0.01) and triglycerides (P < 0.05) were observed 24 weeks after the switch of HAART. The percentage of Group 2 children with increased cholesterol and triglycerides markedly decreased 24 weeks after the switch of HAART (from 46% to 7% and from 54% to 0%, respectively). Proteinuria and glucosuria were not detected in any individual. The mean values of serum creatinine, serum phosphorus, serum bicarbonate, estimated glomerular filtration rate, urinary microalbumin/creatinine, alpha-1-microglobulin/creatinine ratio and maximal tubular phosphate reabsorption remained unchanged in both groups.In HIV-infected children, switching PI to efavirenz and stavudine to tenofovir is virologically and immunologically safe, is not associated with renal impairment and provides a significant improvement in lipid profile." @default.
• W2187888308 created "2016-06-24" @default.
• W2187888308 creator A5000737440 @default.
• W2187888308 creator A5027702804 @default.
• W2187888308 creator A5032927697 @default.
• W2187888308 creator A5056153275 @default.
• W2187888308 creator A5073718294 @default.
• W2187888308 creator A5079688648 @default.
• W2187888308 creator A5085324118 @default.
• W2187888308 creator A5085325102 @default.
• W2187888308 creator A5085472795 @default.
• W2187888308 date "2005-11-01" @default.
• W2187888308 modified "2023-10-16" @default.
• W2187888308 title "Improvement in Dyslipidaemia after Switching Stavudine to Tenofovir and Replacing Protease Inhibitors with Efavirenz in HIV-Infected Children" @default.
• W2187888308 cites W1977705956 @default.
• W2187888308 cites W1981185527 @default.
• W2187888308 cites W1987818325 @default.
• W2187888308 cites W1995988453 @default.
• W2187888308 cites W2024720867 @default.
• W2187888308 cites W2038717450 @default.
• W2187888308 cites W2050999867 @default.
• W2187888308 cites W2053407562 @default.
• W2187888308 cites W2054385676 @default.
• W2187888308 cites W2057394385 @default.
• W2187888308 cites W2071909247 @default.
• W2187888308 cites W2076768567 @default.
• W2187888308 cites W2079156668 @default.
• W2187888308 cites W2083116747 @default.
• W2187888308 cites W2084332399 @default.
• W2187888308 cites W2107014597 @default.
• W2187888308 cites W2126311717 @default.
• W2187888308 cites W2145880414 @default.
• W2187888308 cites W2159584933 @default.
• W2187888308 cites W2163955993 @default.
• W2187888308 cites W2316412239 @default.
• W2187888308 cites W2318180004 @default.
• W2187888308 cites W2318289184 @default.
• W2187888308 cites W2321852728 @default.
• W2187888308 cites W2324473093 @default.
• W2187888308 cites W2325577815 @default.
• W2187888308 cites W2330042106 @default.
• W2187888308 cites W2334153995 @default.
• W2187888308 cites W2337376130 @default.
• W2187888308 cites W2487039045 @default.
• W2187888308 doi "https://doi.org/10.1177/135965350501000807" @default.
• W2187888308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16430197" @default.
• W2187888308 hasPublicationYear "2005" @default.
• W2187888308 type Work @default.
• W2187888308 sameAs 2187888308 @default.
• W2187888308 citedByCount "40" @default.
• W2187888308 countsByYear W21878883082012 @default.
• W2187888308 countsByYear W21878883082013 @default.
• W2187888308 countsByYear W21878883082014 @default.
• W2187888308 countsByYear W21878883082015 @default.
• W2187888308 countsByYear W21878883082016 @default.
• W2187888308 countsByYear W21878883082017 @default.
• W2187888308 countsByYear W21878883082018 @default.
• W2187888308 countsByYear W21878883082022 @default.
• W2187888308 crossrefType "journal-article" @default.
• W2187888308 hasAuthorship W2187888308A5000737440 @default.
• W2187888308 hasAuthorship W2187888308A5027702804 @default.
• W2187888308 hasAuthorship W2187888308A5032927697 @default.
• W2187888308 hasAuthorship W2187888308A5056153275 @default.
• W2187888308 hasAuthorship W2187888308A5073718294 @default.
• W2187888308 hasAuthorship W2187888308A5079688648 @default.
• W2187888308 hasAuthorship W2187888308A5085324118 @default.
• W2187888308 hasAuthorship W2187888308A5085325102 @default.
• W2187888308 hasAuthorship W2187888308A5085472795 @default.
• W2187888308 hasBestOaLocation W21878883081 @default.
• W2187888308 hasConcept C126322002 @default.
• W2187888308 hasConcept C134018914 @default.
• W2187888308 hasConcept C142462285 @default.
• W2187888308 hasConcept C203014093 @default.
• W2187888308 hasConcept C2522874641 @default.
• W2187888308 hasConcept C2777869810 @default.
• W2187888308 hasConcept C2778163477 @default.
• W2187888308 hasConcept C2778913445 @default.
• W2187888308 hasConcept C2779889181 @default.
• W2187888308 hasConcept C2780593183 @default.
• W2187888308 hasConcept C2781432083 @default.
• W2187888308 hasConcept C2993143319 @default.
• W2187888308 hasConcept C3013748606 @default.
• W2187888308 hasConcept C71924100 @default.
• W2187888308 hasConcept C86803240 @default.
• W2187888308 hasConcept C90924648 @default.
• W2187888308 hasConceptScore W2187888308C126322002 @default.
• W2187888308 hasConceptScore W2187888308C134018914 @default.
• W2187888308 hasConceptScore W2187888308C142462285 @default.
• W2187888308 hasConceptScore W2187888308C203014093 @default.
• W2187888308 hasConceptScore W2187888308C2522874641 @default.
• W2187888308 hasConceptScore W2187888308C2777869810 @default.
• W2187888308 hasConceptScore W2187888308C2778163477 @default.
• W2187888308 hasConceptScore W2187888308C2778913445 @default.
• W2187888308 hasConceptScore W2187888308C2779889181 @default.
• W2187888308 hasConceptScore W2187888308C2780593183 @default.
• W2187888308 hasConceptScore W2187888308C2781432083 @default.
• W2187888308 hasConceptScore W2187888308C2993143319 @default.
• W2187888308 hasConceptScore W2187888308C3013748606 @default.

• next